


Emerging Technologies in Toxicity Testing: How will this Impact Risk Assessment?

Dr. Christopher J. Portier


Senior Advisor to the Director

Head, Laboratory of Environmental Systems Biology


National Institute of Environmental Health Sciences




Evaluation of the weight of the evidence - IARC



Human data predominates, but all data is used




Systems Biology for the Individual




Gohlke and Portier (2006)


Research and the Human Model




Research and the Human Model




Emerging Screening Tools and the Risk Assessment Process






What constitutes a positive? Should it be a single number?





Shockley et. al.. SOT 2010

HTS Analyses



Reproducibility








Species
Concordance

ToxScores: combining information to set priorities

Example ToxScores prioritizing chemicals for Cancer, Systemic, Reproductive or Developmental testing, respectively.


$$\text{ToxScore} = \sum_1^C w_c * \text{chemProp}_c + \sum_1^I w_i * \text{assay}_i + \sum_1^P w_p * \text{pathway}_p + \sum_1^E w_e * \text{dosimetry}_e$$



Commercial Tools: GeneGo (an example)

- Chemical Reports
 - Major Metabolites
 - 76 QSAR predictions
 - Protein binding
 - Cancer
 - Alzheimer's
 - Etc
 - Compounds predicted to have similar activity
 - For both parent and metabolites
 - Possible cellular (receptors, proteins, etc.) targets
 - Both parent and metabolites
 - Functional pathways likely to be targeted

Comparison of the average performance of eight different statistical classification methods



How good is good enough?

The predictive capacity of the 3T3 Neutral Red Uptake assay to identify substances with acute oral LD50 > 2000 mg/kg

| | TP | FP | FN | TN | Sens | Spec | Acc | PPV | NPV |
|------|----|----|----|----|------|------|-----|-----|-----|
| JRC | 23 | 14 | 2 | 12 | 92 | 46 | 69 | 62 | 86 |
| HSL | 18 | 14 | 1 | 11 | 95 | 44 | 66 | 56 | 92 |
| IIVS | 24 | 17 | 1 | 12 | 96 | 41 | 67 | 59 | 92 |

TP: True


Positive

FP: False Positive

FN: False Negative

TN: True Negative

Identifying Important Disease Pathways




Genetics, Pathways and Human Disease

- Observations
 - Genetic polymorphisms associated with human diseases
 - Example: ALDH2 isoenzyme polymorphism (mutated form) ALDH2*2 is unable to complete phase 2 metabolism of alcohol leading to increased acetaldehyde levels in blood resulting in increased blood pressure and flushed appearance
 - Part of a pathway related to glycolysis and gluconeogenesis
 - Other aspects of this pathway can lead to increases in acetaldehyde
 - So can biofuels?
 - All of these should be associated with the same symptoms (or phenotype or disease)
 - If chemicals block the activity of ALDH2, they should also increase risk of the same phenotype

Genetic Association Database


geneticassociationdatabase.nih.gov

- The Genetic Association Database is a gene-centered archive of published scientific papers on human genetic association studies.
- Database Contents
 - 28347 records on human gene-phenotype (mostly complex disease) relationships
- Data used in our analysis
 - Manual phenotype grouping and better annotation
 - 8,825 unique associations between 2088 genes and 208 disease phenotypes




Unsupervised Clustering of Pathways with Phenotypes


Gohlke et al. (BMC Systems Biology, 2009)



Cancer Pathways



A Subway Map of Cancer Pathways Hahn and Weinberg, Nature Reviews, 2002



04115 7/23/07




References and links


Comparative Toxicogenomics Database

<http://ctd.mdibl.org/>

- Interactions between environmental factors and genes/proteins in diverse organisms are curated from the published literature using both algorithm based methods as well as manual curation.
- Environmental factor identifiers used in the literature are annotated using MeSH chemical terms.




Mattingly et al. 2006. Toxicol Sci. 92(2):587-95.



B.

Metabolic Syndrome Cluster



Significance in Adipocytokine and PPAR signaling define this cluster:

- 13 are retinoids (including 4 antineoplastic agents).
- 4 are known PPAR alpha/gamma antagonist/agonists:
- 2 are used to treat hyperlipidemia and insulin resistance
- 1 is a Bisphenol A derived epoxy (BADGE)
- 2 are anti-psychotics known to cause weight gain
- Essential omega 3 fatty acids

Neurologic Disease Cluster

- Phenotypes

- Aggression
- Alcohol Abuse
- Anxiety Disorder
- Attention Deficit Disorder
- Autism
- Bipolar Affective Disorder
- Depression
- Huntington's Disease
- Migraine
- Mood Disorders
- Obsessive Compulsive Disease
- Personality Traits
- Schizophrenia
- Substance Abuse
- Suicide
- Tourette Syndrome


- Exposures

- D 21266 (amine)
- Plicamycin
- Nafenopin
- Naphthyridines
- Nordihydroguaiaretic Acid
- Nystatin
- Organophosphorus Compounds
- Oxygen
- Pentazocine
- Pentobarbital
- Pilocarpine

Screening new chemicals for activity

- Pure prediction from a computational model
- Screening using HTS, geneomics and a variety of other tools
 - Look to see what it predicts for activity from a model like ours
 - Look to see what chemicals have the same activity and use a toxic equivalency factors approach


Chemicals linked to breast cancer




Enriched Human Susceptibility Pathways Breast Cancer

| <i>KEGG Pathway ID</i> | <i>Pathway description</i> | <i>SEPEA_NT3</i> | <i>SEPEA_NT3*</i> |
|----------------------------|---------------------------------------|------------------|-------------------|
| path:hsa04370 | vegF signalling pathway | 1.69E-04 | 5.14E-04 |
| path:hsa04662 | B-cell receptor signalling | 3.32E-04 | 3.51E-04 |
| path:hsa04630 | Jak Stat signalling | 8.91E-04 | 0.0417 |
| path:hsa04520 | Adherens junction | 0.0014 | 0.1438 |
| path:hsa04810 | Regulation of actin cytoskeleton | 0.0027 | 0.0717 |
| path:hsa04150 | mTOR signalling | 0.0047 | 0.0052 |
| path:hsa04664 | Fc epsilon RI signalling | 0.0081 | 5.99E-04 |
| path:hsa04510 | Focal adhesion | 0.0103 | 0.0648 |
| path:hsa04012 | ErbB signalling | 0.0103 | 8.51E-04 |
| path:hsa04210 | Apoptosis | 0.0108 | 7.97E-04 |
| path:hsa03440 | Homologous recombination | 0.0147 | 0.0016 |
| path:hsa04660 | T cell receptor signalling | 0.0182 | 0.001 |
| path:hsa04010 | MAPK signalling | 0.0183 | 0.0183 |
| path:hsa04910 | insulin signalling | 0.0191 | 0.0032 |
| path:hsa04514 | Cell adhesion molecules | 0.0274 | 0.2407 |
| path:hsa04115 | P53 signalling | 0.0306 | 0.0093 |
| path:hsa04620 | Toll-like receptor signalling pathway | 0.0391 | 0.0193 |


Estradiol Interactome



Identifying and Screening Pathways



Finding targets for screening Selective gene over-expression





Commercial Tools: GeneGo (an example)

- Chemical Reports
 - Major Metabolites
 - 76 QSAR predictions
 - Protein binding
 - Cancer
 - Alzheimer's
 - Etc
 - Compounds predicted to have similar activity
 - For both parent and metabolites
 - Possible cellular (receptors, proteins, etc.) targets
 - Both parent and metabolites
 - Functional pathways likely to be targeted


Identifying Important Disease Pathways

Short Term Assay
in Rodents +
'omics



Sets of Pathways

Identify Pathways
Related to Rodent
Short-term Response




Incidence of Neoplasms and Nonneoplastic Lesions of the Liver in Rats in the 2 Year Feed Study of 1-Amino-2,4-dibromanthraquinone (continued)

| | 0 ppm | 2,000 ppm | 8,000 ppm | 18,000 ppm |
|---|-----------|-------------|-------------|-------------|
| Female (continued) | | | | |
| 2 Year Study (continued) | | | | |
| Number Examined | 50 | 40 | 80 | 48 |
| Hepatocellular Adenoma (Multiple) | 0 | 18** | 39** | 22** |
| Hepatocellular Adenoma (Single or Multiple) | | | | |
| Overall rate | 0.00 (0%) | 20.40 (70%) | 47.50 (70%) | 29.40 (60%) |
| Tumored rate | 0.00 (0%) | 23.32 (72%) | 29.38 (70%) | 31.25 (65%) |
| Adjusted rate | 0.00% | 75.5% | 83.7% | 83.6% |
| First incidence (days) | 3 | 400 | 275 | 318 |
| Logistic regression test | P=0.001 | P=0.001 | P=0.001 | P=0.001 |

Cancer
Response in
Chronic Bioassay

Short-Term to Long-
Term Prediction Model



Predict
Chronic
Exposure
Response

Statistic for
Testing

Dose-
Response


Microarray data from B6C3F₁ mice following 90 day exposure

| Chemical | Short Name | NTP No. | Route ^a | Dose | Tumors |
|--|------------|------------------|--------------------|-----------------------|--------|
| 1-Amino-2,4-dibromoanthraquinone | ADBQ | 383 | Food | 20,000 ppm | Liver |
| Methylene Chloride | MECL | 306 | Inhalation | 4,000 ppm | Liver |
| N-Methylolacrylamide | MACR | 352 | Gavage (Water) | 50 mg/kg | Liver |
| Tris(2,3-dibromopropyl)phosphate | TDPP | 76 | Food | 1,000 ppm | Liver |
| 2,2-Bis(bromomethyl)-1,3-propanediol | BBMP | 452 | Food | 1,250 ppm | Other |
| 1,2-Dibromoethane | DBET | 86 | Gavage (CO) | 62 mg/kg | Other |
| Ethylene Oxide | ETOX | 326 | Inhalation | 100 ppm | Other |
| Naphthalene | NPTH | 410 | Inhalation | 30 ppm | Other |
| Vanadium Pentoxide | VANP | 507 | Inhalation | 2.0 mg/m ³ | Other |
| 1,4-Dichlorobenzene | DCBZ | 319 | Gavage (CO) | 600 mg/kg | Liver |
| Propylene glycol mono- <i>t</i> -butyl ether | PGBE | 515 | Inhalation | 1,200 ppm | Liver |
| Tetrafluoroethylene | TFEL | 450 | Inhalation | 1,250 ppm | Liver |
| 1,2,3-Trichloropropane | TCPN | 384 | Gavage (CO) | 60 mg/kg | Liver |
| 2-Chloromethylpyridine hydrochloride | CMPH | 178 | Gavage (Water) | 250 mg/kg | No |
| Diazinon | DIAZ | 137 | Food | 200 ppm | No |
| Iodoform | IODO | 110 | Gavage (CO) | 93 mg/kg | No |
| Malathion | MALA | 24 | Food | 14,800 ppm | No |
| 4-Nitroanthranilic acid | NAAC | 109 | Food | 10,000 ppm | No |
| Tetrafluoroethane | TFEA | --- ^d | Inhalation | 50,000 ppm | No |
| Trichlorofluoromethane | TCFM | 106 | Gavage (CO) | 3,925 mg/kg | No |
| Air | ACON | | Inhalation | | |
| Corn oil | CCON | | Gavage (CO) | | |
| Feed | FCON | | Food | | |
| Water | WCON | | Gavage (Water) | | |


Predicted Liver Cancer from Microarray Data


Liver Carcinogens

Above red line - clearly positive
Below blue line - clearly negative
X - actual data prediction
Green range - x-validation range




Predicted Liver Cancer from Microarray Data






Evaluating Dose-Response Patterns


Methylene Chloride




Naphthalene




1,4-Dichlorobenzene




1,2,3-Trichloropropane



Propylene glycol mono-*t*-butyl ether



New types of biomarkers in blood: tissue-specific release of mRNA into blood



Wetmore et al., Hepatology 2010 (in press)

Issues to Consider

- Predictions are model dependent
 - Do we have a process for model review?
- Broaden the use of human data and human approaches in toxicology
 - Genetics
 - Epidemiology
 - Gene expression profiling
 - GWAS studies
- Validation?
 - Decisions are context dependent and data dependent
 - Is it a question of replacing an assay or not needing one because of other information?
- Scalable Approaches
 - Improved systems biology, improved human genetics, genomics, disease linkage, epidemiology data, etc.

Advantages and Disadvantages to improving toxicity testing

- More compounds, more compounds, more compounds
- Focus intense testing on chemicals likely to be most important
- Screen new commercial formulations (e.g. green chemistry) before investing in a technology
- Dataset for risk assessment will be increasingly complex...
 - Need a complex measure for deciding if something is a hazard
 - NOEL's are unlikely to be useful in setting standards
 - Focus may finally come to complex exposures
 - Dose-response in itself will be complex
 - Societal decisions on whether a pattern of activity is adverse will be difficult
- Lots of public concern caused by misapplying models to product formulations